


PHARMACEUTICAL 2017

CELGENE CORP DE Rank 50 of 313





PHARMACEUTICAL 2017



CELGENE CORP DE Rank 50 of 313

The relative strengths and weaknesses of CELGENE CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CELGENE CORP DE compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 260% points. The greatest weakness of CELGENE CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 59%, being 476% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	10,867,500
Cost of Goods Sold	0
Intangible Assets	15,257,600
Liabilities, Current	2,959,200
Liabilities, Non-Current	15,559,700
Other Assets	1,030,700
Other Compr. Net Income	-348,600
Other Expenses	1,808,200
Other Liabilities	2,967,400
Other Net Income	-294,000
Property and Equipment	929,800
Research and Development	4,470,100
Revenues	11,229,200
Selling, General and Administrative Expense	2,657,700

Output Variable	Value in 1000 USD
Assets	28,085,600
Liabilities	21,486,300
Expenses	8,936,000
Stockholders Equity	6,599,300
Net Income	1,999,200
Comprehensive Net Income	1,824,900
Economic Capital Ratio	59%